Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era.

cancer drivers cancer genes multiscale analysis personalized medicine variants of unknown significance

Journal

FEBS letters
ISSN: 1873-3468
Titre abrégé: FEBS Lett
Pays: England
ID NLM: 0155157

Informations de publication

Date de publication:
12 2020
Historique:
received: 03 11 2019
revised: 23 01 2020
accepted: 09 02 2020
pubmed: 3 4 2020
medline: 4 6 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

One of the key challenges of cancer biology is to catalogue and understand the somatic genomic alterations leading to cancer. Although alternative definitions and search methods have been developed to identify cancer driver genes and mutations, analyses of thousands of cancer genomes return a remarkably similar catalogue of around 300 genes that are mutated in at least one cancer type. Yet, many features of these genes and their role in cancer remain unclear, first and foremost when a somatic mutation is truly oncogenic. In this review, we first summarize some of the recent efforts in completing the catalogue of cancer driver genes. Then, we give an overview of different aspects that influence the oncogenicity of somatic mutations in the core cancer driver genes, including their interactions with the germline genome, other cancer driver mutations, the immune system, or their potential role in healthy tissues. In the coming years, this research holds promise to illuminate how, when, and why cancer driver genes and mutations are really drivers, and thereby move personalized cancer medicine and targeted therapies forward.

Identifiants

pubmed: 32239503
doi: 10.1002/1873-3468.13781
pmc: PMC7529711
mid: NIHMS1584848
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4233-4246

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM118187
Pays : United States

Informations de copyright

© 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

Cancer Cell. 2019 Apr 15;35(4):559-572.e7
pubmed: 30905761
Nat Genet. 2017 Jan;49(1):10-16
pubmed: 27869828
Nat Methods. 2013 Nov;10(11):1081-2
pubmed: 24037244
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Genome Med. 2014 Jul 31;6(7):56
pubmed: 25177370
PLoS One. 2013 Oct 30;8(10):e77945
pubmed: 24205039
BMC Genomics. 2013;14 Suppl 3:S3
pubmed: 23819870
Nat Methods. 2013 Nov;10(11):1108-15
pubmed: 24037242
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Cancer Res. 2016 Jul 1;76(13):3719-31
pubmed: 27197156
Nat Genet. 2015 Jun;47(6):569-76
pubmed: 25915600
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Nat Rev Cancer. 2004 Mar;4(3):177-83
pubmed: 14993899
Cell. 2014 Jun 19;157(7):1509-14
pubmed: 24949964
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
Cold Spring Harb Perspect Med. 2017 Dec 1;7(12):
pubmed: 28490542
Nat Genet. 2015 Feb;47(2):106-14
pubmed: 25501392
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Cell. 2017 Nov 30;171(6):1272-1283.e15
pubmed: 29107334
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
Science. 2018 Nov 23;362(6417):911-917
pubmed: 30337457
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Sci Rep. 2019 Jan 22;9(1):263
pubmed: 30670742
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Sci Rep. 2013 Oct 02;3:2650
pubmed: 24084849
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
Sci Transl Med. 2015 Apr 15;7(283):283ra54
pubmed: 25877892
Cell. 2013 Jan 31;152(3):633-41
pubmed: 23374354
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
NPJ Breast Cancer. 2017 Nov 22;3:46
pubmed: 29177190
Cell Syst. 2019 Jul 24;9(1):9-23.e8
pubmed: 31202631
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Elife. 2017 Jul 07;6:
pubmed: 28686159
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Science. 2015 May 22;348(6237):880-6
pubmed: 25999502
Am J Hum Genet. 2018 May 3;102(5):943-955
pubmed: 29706350
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Cell. 2018 Apr 5;173(2):305-320.e10
pubmed: 29625049
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Cancer Discov. 2017 Apr;7(4):410-423
pubmed: 28188128
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15259-64
pubmed: 22949682
PLoS Comput Biol. 2015 Oct 20;11(10):e1004518
pubmed: 26485003
Cancer Res. 2018 Oct 1;78(19):5527-5537
pubmed: 30275052
Cancer Cell. 2016 Aug 8;30(2):214-228
pubmed: 27478040
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Neuro Oncol. 2019 Mar 18;21(4):451-461
pubmed: 30624711
N Engl J Med. 2015 Feb 12;372(7):601-612
pubmed: 25671252
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Nat Genet. 2009 Apr;41(4):450-4
pubmed: 19287385
Genome Med. 2012 Nov 26;4(11):89
pubmed: 23181723
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Cancer Res. 2011 Apr 1;71(7):2423-7
pubmed: 21292812
Nature. 2010 Apr 15;464(7291):993-8
pubmed: 20393554
Bioinformatics. 2011 Jan 1;27(1):95-102
pubmed: 21045073
Cancer Cell. 2018 Oct 8;34(4):549-560.e9
pubmed: 30300578
Nat Genet. 2016 Oct;48(10):1288-94
pubmed: 27618449
Cancer Cell. 2018 Mar 12;33(3):450-462.e10
pubmed: 29533785
Cell. 2019 Apr 18;177(3):608-621.e12
pubmed: 30955891
Genome Med. 2017 Jan 23;9(1):4
pubmed: 28115009
Bioinformatics. 2013 Jun 15;29(12):1504-10
pubmed: 23620363
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
PLoS Comput Biol. 2010 Jan 15;6(1):e1000641
pubmed: 20090828
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):7899-906
pubmed: 18524956
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Cell Rep. 2016 Oct 18;17(4):1171-1183
pubmed: 27760319
Cancer Cell. 2017 Jun 12;31(6):820-832.e3
pubmed: 28528867
Nat Genet. 2016 Aug;48(8):827-37
pubmed: 27294619
Mol Cell. 2018 Jul 5;71(1):178-190.e8
pubmed: 29979965
Cancer Res. 2007 Jun 1;67(11):5134-40
pubmed: 17545591
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
Science. 2019 Mar 15;363(6432):1150-1151
pubmed: 30872507
Nucleic Acids Res. 2011 Sep 1;39(17):e118
pubmed: 21727090
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
PLoS Comput Biol. 2014 Feb 06;10(2):e1003460
pubmed: 24516372
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Nat Rev Cancer. 2017 Apr;17(4):239-253
pubmed: 28256574
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Bioinformatics. 2011 Aug 1;27(15):2147-8
pubmed: 21685053
Am J Hum Genet. 2008 Apr;82(4):949-58
pubmed: 18371930
Genome Biol. 2019 Dec 24;20(1):298
pubmed: 31874648
Genome Biol. 2016 Jun 23;17(1):129
pubmed: 27333808
Nat Genet. 2018 Oct;50(10):1381-1387
pubmed: 30224644
Genome Biol. 2012 Dec 22;13(12):R124
pubmed: 23383675
Genetics. 2015 Jun;200(2):413-22
pubmed: 25823446
Cell. 2018 Oct 4;175(2):416-428.e13
pubmed: 30245014
Science. 2019 Jun 07;364(6444):
pubmed: 31171663
Trends Genet. 2019 Jul;35(7):515-526
pubmed: 31128889
Nature. 2018 Jul;559(7714):400-404
pubmed: 29988082
Genome Biol. 2008;9 Suppl 1:S4
pubmed: 18613948
Nat Genet. 2016 Dec;48(12):1581-1586
pubmed: 27776117
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346

Auteurs

Eduard Porta-Pardo (E)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.
Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.

Alfonso Valencia (A)

Barcelona Supercomputing Center (BSC), Barcelona, Spain.
Institucio Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.

Adam Godzik (A)

Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH